← All Biomarkers
EGFR exon 19 deletions
2 drugs Predictive biomarker for patient selection in 9 indications
EGFR exon 19 deletions is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 9 indications including First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib), Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed), First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed). Explore the targeted therapies, indications, testing methods, and companies developing EGFR exon 19 deletions drugs below.
Drugs Targeting EGFR exon 19 deletions
| Drug | Company | Therapeutic Area |
| RYBREVANT | Johnson & Johnson | Oncology |
| TAGRISSO | AstraZeneca | Oncology |
EGFR exon 19 deletions Indications
First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed) First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy (as a single agent) Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapy First-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC First-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapy Metastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy
Companies with EGFR exon 19 deletions Drugs
